.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CNN just said that hurricane Irma is due to hit Miami. I hope that the progressive care stays safe during this.
Seriously, stay safe
If I don't known any shares in the company.
Second off I wouldn't buy it until that five micro Penny Mark
Rip the OTCQB dream.
Super Low Volume.
Non-Existent Bid.
Negative Q2.
Increasing Expenses.
Buy Volume is Suffocating
I believe we'll go below 0.01 soon.
Thank you for your post. It's was a great read with fair and valid points. Even so, RXMD has a record of paying in shares as it sees it as keeping their cash flow stable. Sure, it could maybe pay the money back (though with it turning negative, I have growing concerns), it still could fall back on their bad habits.
The bid is no existent. One person sells and it'll drop like crazy. The Exit door is tiny.
Compared to the turn over that we saw in 2015, RXMD dropped the ball. The way they grew profits was awesome and their growth was great.
Now growth is good but we aren't getting any profits from it.
This is a huge disappointment. Also, you're wrong to think that RXMD is one of the best on otc land because it broke even.
That's laughable.
I see stocks every few days that started around 0.004 or less and are now $+3 and stable.
With the amount of revenue, you'd think this company was good, but it's pathetic that they stopped at their goal (the goal of breaking even).
Also, starting subsidiaries is an awful money hole for the company :/
Rip Cost of sales
Rip missed a zero there. $200,000
Claps hands XD great profits for a years time Lol
Lol $20,000
Let's be honest. We've been saying that since 2015. Is it possible? Sure. Is it likely, I don't personally think so. They have licensing to do business across the US which helps add to their value, but I wouldn't spend money on a company that only makes $50,000 each month.
Unless you were the company supplying RXMD with their basic materials, who would take out a major loan to acquire it.
--------
A merger would be okay, though it's clear that RXMD is more focused on wasting their money creating subsidiaries.
With an average of ~60% in cost of sales (then with the increase to ~75%) it is true that the gross margin could be a 1 off. Even so, the growth that the company is seeing is minuscule in terms of overall profit.
Again, it's possible the next quarterly report could go back to operating profitable, but it is still on the brink of going negative again. Not a very safe way to do business imo.
PS. It seems the company is putting more money into the marketing, productions, and inventory management into their products thus increasing the cost of sales.
It's also possible we could see a continued decline into the negatives.
Had a consultant message me this. Anyone looking to discuss these statements.
To be clear, these statements aren't my own. I simply seem to find truth.
"RXMD has a history of paying creditors with shares (ie: Tarpon Bay Partners), and continue to do this with marketing firms like Midam and First Look Equities. They also signed a convertible note with Chicago Ventures for $2M taken in $250K tranches that began July-2016. And they also pay stock-based compensation to various consultants. They have a Managing partner who is also paid this way through his company Stark Consulting, in addition to taking a salary. This is Armen Karapetyan who lost his FINRA license over dirty stock trades when he was a penny stock broker. He also owns over half the voting shares thanks to the company having issued him preferred stock recently. RXMD is your run-of-the mill dirty dealing penny stock and the investors on IHub don't sound like they've been around the block yet on these dealers. Seems their attorney Jeffrey Klein was also indicted on securities charges."
My question mainly is, is RXMD diluting shares with these $250,000 trenches up to the amount of $2,000,000?
I haven't kept very up-to-date with this news and would like to crowdsourcing for info.
Thanks in advance!
True but they were making pennies on the dollar for their sales. I saw this as potentially dangerous as profits were still close to the $0 mark.
As we've seen, a crossover occurred so my instinct was correct (aka this company didn't make a profit this corner.
The next quarter will be the tell all. If the cost of sales is ~75%, then it's likely the company will be hitting a loss. If they get it down to ~60% like in the past, we'd be much better off. (Aka atleast operating profitable;barely)
That's very unrealistic XD
We all wish it'd make a run to $50 but that won't happen
If it continues to slip quickly, I probably will. I'll be keeping an eye on it.
What was the reason for the company taking that on?
There's actually a lot of factual evidence on what I wrote. Whether you use this information to make a decision is up to you though.
Stop spewing false information and slandering facts.
LOLOL please refer to my source to help you understand where all of my number come from and how I received all of my calculations.
The PR is clearly stated to be the Q2 from 2017.
If the company was able to get their cost of sales down, then this would be an awesome stock. When they're spending +70% on cost of sales (not including admin expenses), there's a huge problem.
As an investor, I can't be happy knowing the company is making a profit of ~$50,000 (and more recently a loss).
I agree that this company has looped. Honestly, I think this stock jumped because of how consolidation stopped added with the company becoming operating profitably for the first time in a very long time.
My question is, how far will the stock fall now that it isn't profitable anymore?
Engh, it'll be a good show to watch while I'm at work.
If the company came out tomorrow and said that it found 1 mil under its bed, then yes. Otherwise, this will not happen.
I haven't looked into RXMD and the whole creditors' situation, but isn't RXMD paying with shares? Isn't that technically dilution. Honest question o.o
Wouldn't you consider the short and long term liabilities as short and long term debt?
I mean heck! It's not a credit .=.
My Possible Buy In?
I expect this downward move to continue as I don't expect any good news to come out, with the best case scenario occurring with the q3 report. Even so, news has notoriously not been able to move the stock since it's been above the 0.01 region.
I'll put a possible buy-in target at 0.008, though this would have to be a slow and gradual decline. If this fall turns into a crash, I'll buy in at the eventual low and hold from there. My preferred range would be around 0.005-0.004.
___________
If it doesn't happen, then so be it...
I won't touch this stock otherwise though
Just gonna put some quick technical analysis here. Looking back at the resistance lines from late 2015 (as we're retesting these lines again), we see that RXMD has broken below the resistance line at 0.0139 from 11/30/15.
The next major resistance line below that is at 0.0084 from 11/9/15. Under that is 0.0057 from 10/19/15.
Currently, the stock is between the range of 0.0084 and 0.0139.
It is possible that RXMD might retest 0.0139 as a sign of strength, though there isn't much to suggest that it has the ability to break 0.0139.
On the other hand, there is evidence that RXMD will retest the lower 0.0084 regions. After all, there is a clear downward trend coupled with lower average buy volumes that showing fleeting support.
________________
My boolean bands are putting the current range between 0.016 and 0.0116.
RSI is currently 44.1513 thus showing that this downward move wasn't oversold.
Have you factored in expenses? Literally ~74.957% of that revenue goes to cost of sales alone. Factor in the ~27.471% in other selling, general, and administrative expenses and this stock is making nothing in profit.
74.957 + 27.471 = 102.428%
This company is running at an overall loss again!
They make $22,000,000 in revenue and would have ~$22,534,160 in expenses. Back to the micro (and possibly nano) pennies we go :/
Source
90k isn't going to move this pps XD
Fundamentals vs Technicals.
I think technicals are more important ATM
They can accumulate all they want into a loss XD still doesn't change the fact that the .05+ dream is dead atm.
With the companies cost of sales increase, its back into negative territory.
GG was nice while it lasted!
Rip
With the recent PRs with management switching out, there is definitely concern
No Discussion?
Renewable Energy and Power, Inc. (RBNW) Forward-Looking Analysis
Read Full Article Here!
Business Information:
Renewable Energy and Power, Inc.
Ticker: RBNW
PPS: 0.0705 a/o 8/16/2017
Up 0.0526 or (+293.85%)
Market Value: $6,117,275 a/o August 15, 2017
Authorized Shares: 750,000,000 a/o April 26, 2017
Outstanding Shares: 86,769,860 a/o August 08, 2017
#111 3395 Cheyenne Ave
N. Las Vegas, NV 89032
Phone Number: 1(702)685-9524
Website: http://www.reappower.com
Fundamental Analysis:
According to Renewable Energy and Powers’ website, RBNW is dedicated to a cleaner, greener planet. They provide the best alternatives to traditional and fossil fuel power through our commitment to solar energy and LED lighting. RBNW strives to reduce their collective carbon footprint, so our environment is safe, renewable, and cost efficient. They are in the business of generating and cultivating emerging technology in renewable energy, producing effective and reliable energy, and power solutions to consumers and corporations worldwide.
Read Full Article Here!
RBNW has LEDLItes USA, Sol-HY, and Power Stac as their main product lines. LEDLites USA are green energy solutions that provide their customers greater product functionality and superior cost-benefits for their LED Lighting. Their second product line, Sol-HY, uses Tandem Solar Cells that provide twice the solar energy conversion to electricity as compared to standard silicon solar cells. These patented processes increase solar cell output, interconnect reliability, provide their electrical efficiency and significant production cost savings while conserving expensive semiconductor materials. Finally, Power Stac offers Green Energy storage by employing proprietary new technologies in Re-Dox Battery Energy Storage Systems.
Renewable Energy and Powers’ Management:
Mr. Donald M. Macintyre, Chairman, Chief Executive Officer (CEO), and President
Bruce Parsons, Chief Financial Officer (CFO), Treasurer, and Director
Mr. Bruce Macintyre, Vice President of Marketing, Secretary, and Director
Mr. Perry Barker, Vice President of Sales and Director
Statistics:
Market Cap (Intraday): 2.12M
Trailing P/E: -0.02
Price/Sales: 2.92
52-Week Change: -95.53%
52-Week High: 0.80
52-Week Low: 0.00009
50-Day Moving Average: 0.1350
200-Day Moving Average: 0.3033
Average Volume (3 Month): 655.27k
Average Volume (10 Day): 3.83m
Read Full Article Here!
Loss* on mobile so can't fix
Uplifting while running at a lose. Great plan 10/10.
Sounds like they want a higher pps to dilute shares
Progressive Care, Inc. (RXMD) 2nd Quarterly Report Analysis
Read Full Article Here
Business Information:
Progressive Care, Inc.
Ticker: RXMD
PPS: 0.0179 a/o 8/14/2017
Up 0.0006 or +3.47%
2nd Quarterly Report:
OTCMarkets RXMD 2nd Quarterly Report Link
First, let’s start off with Progressive Cares’ consolidated balance sheet (unaudited). RXMD has $514,925 in cash, $1,127,160 in accounts receivable (trade, net), $120 in accounts receivable (other), $406,350 in inventory (net), $56,730 in prepaid expenses, $316,834 in property and equipment (net), and $25,746 in total other assets (deposits). This gives Progressive Care a total of $2,447,865 for their total assets.
Next, we have Progressive Cares’ liabilities. RXMD has $1,410,832 in accounts payable and accrued liabilities, $85,107 in deferred rent liability, $298,081 in notes payable (net of unamortized debt discount and debt issuance costs), $17,836 in capital lease obligations (current portion), $186,130 in unearned revenue, and $7,840 in derivative liability. This gives RXMD a total of $2,005,826 in total current liabilities. Next, we see that RXMD has a long-term liability in the amount of $106,022 for capital lease obligations (net of current portion), thus giving RXMD $2,111,848 in total liabilities. RXMD has a total stockholders’ equity of $336,017 and a total liabilities and stock holders’ equity of $2,447,865.
Read Full Article Here
Finally, let’s look at Progressive Cares’ consolidated statements of income (income statement; unaudited). For the three month period ending on June 30, 2017, we see that RXMD made $5,173,064 in their net sales. RXMD then had $ 3,877,551 for their cost of sales, giving RXMD a gross profit of $1,295,513.
$5,173,064 100% (Sales, Net)
($3,877,551) ~-74.957% (Cost of Sales)
=$1,295,513 ~25.043% (Gross Profit)
Next, we have RXMD’s selling, general, and administrative expenses. RXMD has $8,484 in bad debt expenses, and $1,412,600 in other selling, general, and administrative expenses. This gives RXMD a (Loss) income from operations amounting in ($125,571).
$1,295,513 ~25.043% (Gross Profit)
-($1,421,084) ~-27.471% (Other selling, general, and administrative expenses; Taken from net sales)
=($125,571) ~-102.427% (Loss from operations; Taken from net sales)
RXMD then has an additional loss from total other income (expenses) in the amount of ($12,979). This gives RXMD a net loss of ($138,550).
=($125,571) ~-102.427% (Loss from operations)
-($12,979) ~0.2509% (Total other income(expenses, net)
=($138,550) ~-102.678% (Net Loss)
Read Full Article Here
Maybe so but they're out there. The flippers and "bear money makers" are out there
Read Full Article Here!
Business Information:
Michael James Enterprises, Inc.
Ticker: MJTV
PPS: 0.001762 a/o 8/13/2017
Up 0.00076 or +76.20%
Market Value: $41,296 a/o August 11, 2017
Authorized Shares: 980,000,000 a/o June 06, 2017
Outstanding Shares: 23,463,424 a/o June 06, 2017
Float: 15,000,000 a/o June 06, 2017
760 Route 10 West
Suite 203
Whippany, NJ 07981
Website: http://www.mjbiotech.com
Phone: (908) 204-0004
Email: info@mjenterprises.com
Fundamental Analysis:
According to OTCMarkets, Michael James Enterprises, Inc. identifies and engages in the development and marketing of consumer products. They are developing six essential oils and other ingredients. The primary product will be VOLUPTAS and is expected to be introduced into the market by the end of 2017 as a female sexual arousal booster. On August 4, 2016, Michael James Enterprises, Inc. also acquired the exclusive rights to the science for the treatment of sleep Apnea utilizing Dronabinal with one other active ingredient.
Michael James Enterprises, Inc.’s Management:
Mr. James M. Farinella, Chairman, Chief Executive Officer & CFO
Ms. Gina Morreale, COO & Director
Ryan Summers, Creative Director
Statistics:
Market Cap (Intraday): 41.34K
Beta: 5.76
52-Week Change: -99.00%
52-Week High: 0.18
52-Week Low: 0.001
50-Day Moving Average: 0.001997
200-Day Moving Average: 0.009871
Average Volume (3 Month): 290.47k
Average Volume (10 Day): 487.23k
Market Analysis:
According to Grand View Research, the U.S. essential oil market size was valued at $3.36 billion in 2015 and is expected to witness an estimated growth rate of 9.0% from 2016 to 2024. Around 200 different types of essential oils are consumed all over the world annually, and the U.S. plays a significant role in overall demand. Increasing consumer disposable incomes and rapid expansion of food and beverage industries are expected to contribute to the demand for natural fragrances and flavors produced.
News:
MJTV looks to be very busy with many articles being released between 12/10/15 and 3/28/17. Interestingly though, we were not able to find any news past the date of 3/28/17.
On 12/15/16, Michael James Enterprises is pleased to report that the company has begun to generate revenue with the release of its first product LUNA. As a proof of concept and market test, MJTV bottled 50 units of LUNA and offered it for sale at a promotional price of $19.95. All 50 bottles sold out within three days with numerous requests for more of the LUNA product.
On 12/22/16, Michael James Enterprises, Inc. reduced their Outstanding Shares by over 40% retiring 9,000,000 Shares from outstanding of 21,659,603 to 12,659,603.
On 1/17/17, Michael James Enterprises, Inc. is pleased to report that it has eliminated more than $1,000,000 of debt and liabilities with the spinoff of BullsNBears Holdings, Inc. on December 27, 2016.
On 2/8/2017, Michael James enterprises, Inc. is extremely pleased to report that as promised on December 22, 2016, CEO, James M. Farinella last week retired 8,425,000 shares. This retiring of shares had the effect of reducing the outstanding number of shares from 25,029,572 down to 16,604,572, a 33.6% reduction.
On 3/9/17, Michael James Enterprises, Inc. is extremely pleased to report that approximately two weeks ago it filed for patent protection for VOLUPTAS.
On 3/13/17, Michael James Enterprises, Inc. is happy to report that it has entered into a design and development agreement with Glove Medical Tech, Inc. of Houston, Texas for the revolutionary female sexual booster VOLUPTAS.
On 3/20/17, Michael James enterprises, Inc. more than doubled the number of units of LUNA sold in the first quarter of 2017.
On 3/22/17, Michael James Enterprises, Inc. is pleased to report that the company has developed two more essential oil alchemy products and is in the final test marketing for the both products. This will bring MJTV essential oil product line to 3 with an additional two more essential oil mixtures to come shortly bringing the total to 5.
On 3/28/17, Michael James Enterprises, Inc. launches, “What is a Beautiful Woman” branding and marketing campaign in advance of the VOLUPTAS market launch.
Filings and Disclosures:
Looking at the 10-Q from June 14, 2017, we first see Michael James Enterprises, Inc.’s’ balance sheets (unaudited). We see that the company has $7,070 in cash and $1,000 for accounts receivable for March 31, 2017. Total Current Liabilities for the company are $1,054,958. Total stockholders’ Equity is at (1,046,888), and total liabilities and stockholders’ equity (DEFICIT) is at $8,070.
Now looking at the consolidated statements of operations (unaudited), we see that the company has no revenue. The company has accumulated $5,669,646 for their total operating expenses. They had a loss of $157,476 for their total other Income (Expenses), bringing their net loss to (5,827,122).
On July 10, 2017, the company released an 8-K stating that on June 27, 2017, Raj Pamnani and James Farinella are resigning from their positions as directors and officers of the company. On June 28, 2017, the company, by written direction of the sole Director, appointed as a Director of the Company Maxine Pierson which was accepted by Ms. Pierson. Ms. Pierson was also elected as Chief Executive Officer. The change of the officers and directors became effective as of July 1, 2017.
On July 31, 2017, the company released an 8-k stating that on July 26, 2017, MJ BIOTECH, INC., entered into a “Binding Letter of Agreement” for the acquisition of Zen Hero, Inc. d/b/a Zen’s Tea House, ZEN HERO business is a formulator of Organic Teas for sale to the public and other businesses. The transaction is anticipated to close within ninety (90) days. The proposed purchase price is a combination of cash ($750,000) and stocks. $400,000 is payable on closing with the balance to be paid based on performance milestones.
Read Full Article Here!
Honestly, I thought the edits would've fixed it, as I agree that the original statement didn't really work the way I want it too.
RXMD is a good long term stock, but I have concerns about shorting it.
Lastly,
These numbers are from OTCMarkets. Are you suggesting that these numbers are fake?